U.S. markets close in 2 hours 47 minutes
  • S&P 500

    4,228.74
    -3.86 (-0.09%)
     
  • Dow 30

    35,009.47
    +231.71 (+0.67%)
     
  • Nasdaq

    13,551.46
    -200.77 (-1.46%)
     
  • Russell 2000

    2,249.73
    -21.90 (-0.96%)
     
  • Crude Oil

    64.96
    +0.06 (+0.09%)
     
  • Gold

    1,837.70
    +6.40 (+0.35%)
     
  • Silver

    27.53
    +0.05 (+0.19%)
     
  • EUR/USD

    1.2160
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5900
    +0.0130 (+0.82%)
     
  • GBP/USD

    1.4137
    +0.0147 (+1.05%)
     
  • USD/JPY

    108.8280
    +0.2460 (+0.23%)
     
  • BTC-USD

    57,640.01
    +89.56 (+0.16%)
     
  • CMC Crypto 200

    1,541.04
    -20.25 (-1.30%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    29,518.34
    +160.52 (+0.55%)
     

Novavax Drops on Reports of Vaccine Delay

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

By Christiana Sciaudone

Investing.com -- Novavax (NASDAQ:NVAX) slumped 7% after reports that it is unlikely to seek emergency use authorization for its Covid-19 vaccine in the U.S. until at least June.

In February, Novavax’s president of research and development, told a Washington Post Live audience that results from the trial were expected “right at the beginning, maybe” of the second quarter, but a regulatory manufacturing issue has hindered progress, The Washington Post reported, citing four people familiar with the situation. That could mean authorization won't come until "well into summer."

Although the U.S. is overflowing with vaccines, countries around the world, including India and Argentina, are seeing their worst pandemic days yet, and the easy-to-store Novavax vaccine could help. Novavax received $1.6 billion in federal funding for the vaccine development.

Novavax has a goal of producing 2 billion doses a year. It hasn't yet produced any viable vaccine.

Related Articles

Novavax Drops on Reports of Vaccine Delay

France stocks higher at close of trade; CAC 40 up 0.01%

Coty's luxury brands return to growth as restrictions ease